The game is nearly up for Clovis Oncology (Nasdaq: CLVS).
Founded in 2009, the Colorado, USA-based biotech has focused on developing and commercializing cancer products but its fortunes have been dependent on the success of the company’s wholly-owned PARP inhibitor, Rubraca (rucaparib).
"We will not have sufficient liquidity to maintain our operations beyond January 2023"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze